SeaStar Medical Holding Corporation (ICU)

NASDAQ: ICU · IEX Real-Time Price · USD
4.35
-0.30 (-6.45%)
Dec 6, 2022 3:59 PM EST - Market closed
-6.45%
Market Cap 59.05M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 13.07M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 25,338
Open 4.47
Previous Close 4.65
Day's Range 4.17 - 4.75
52-Week Range 3.9 - 12.2
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About ICU

SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acu... [Read more]

Industry Biotechnology
Founded 2018
Employees 3
Stock Exchange NASDAQ
Ticker Symbol ICU
Full Company Profile

Financial Performance

Financial Statements

News

SeaStar Medical Bolsters Operational Expertise with Appointment of Thomas R. Mullen as Vice President of Operations a...

DENVER, COLORADO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq:ICU), (“SeaStar Medical” or the “Company”), a medical technology company developing proprietary solutions ...

4 days ago - GlobeNewsWire

SeaStar Medical Appoints Rick Barnett as Chairman of the Board of Directors

DENVER, COLORADO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq:ICU), (“SeaStar Medical” or the “Company”), a medical technology company developing proprietary solutions ...

1 week ago - GlobeNewsWire

SeaStar Medical's Lead Product Candidate, the Selective Cytopheretic Device (SCD), Included in Consensus Statement fo...

– The SCD is currently being evaluated by the FDA for a Humanitarian Device Exemption (HDE) marketing approval for use in children (> 20 kgs) with AKI

4 weeks ago - GlobeNewsWire

SeaStar Medical (NASDAQ: ICU) Commences Trading on Nasdaq Capital Market and Outlines Corporate Strategy and Near-Ter...

– Company advancing clinically proven platform therapy , the Selective Cytopheretic Device (SCD ), to address the life-threatening consequences of hyperinflammation

1 month ago - GlobeNewsWire